ING Groep NV Has $4.64 Million Position in Sarepta Therapeutics, Inc. $SRPT

ING Groep NV lessened its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 50.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 240,800 shares of the biotechnology company’s stock after selling 248,300 shares during the quarter. ING Groep NV’s holdings in Sarepta Therapeutics were worth $4,640,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SRPT. CWM LLC lifted its stake in Sarepta Therapeutics by 4,033.3% during the third quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock worth $1,401,000 after purchasing an additional 70,946 shares during the period. 683 Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 309.1% in the 2nd quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock valued at $11,542,000 after purchasing an additional 510,000 shares during the period. State of New Jersey Common Pension Fund D raised its holdings in shares of Sarepta Therapeutics by 59.9% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock worth $830,000 after buying an additional 18,190 shares in the last quarter. Edgestream Partners L.P. raised its holdings in shares of Sarepta Therapeutics by 870.3% in the 2nd quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company’s stock worth $1,419,000 after buying an additional 74,427 shares in the last quarter. Finally, Privium Fund Management B.V. bought a new position in shares of Sarepta Therapeutics during the 2nd quarter worth approximately $698,000. 86.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SRPT. Barclays started coverage on Sarepta Therapeutics in a research report on Wednesday, January 28th. They issued an “equal weight” rating and a $20.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sarepta Therapeutics in a report on Monday, December 29th. Royal Bank Of Canada lifted their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th. Robert W. Baird reduced their price target on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Finally, Mizuho raised shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $19.00 to $26.00 in a report on Wednesday, November 5th. Nine research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $33.84.

Insider Activity at Sarepta Therapeutics

In related news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the sale, the chief operating officer owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 7.60% of the stock is owned by company insiders.

Sarepta Therapeutics Stock Down 3.1%

Shares of NASDAQ:SRPT opened at $17.40 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.82 billion, a P/E ratio of -5.78, a P/E/G ratio of 0.45 and a beta of 0.39. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $111.21. The company’s 50-day moving average price is $21.20 and its two-hundred day moving average price is $20.10.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.